Letter to the editor concerning the article: “Comparative safety and benefit-risk profile of biologics and oral treatments for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data”

Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

“…The issues raised here reiterate our previous concerns with the NMA conducted by Shear et al [ 3 ]. We continue to emphasize the importance of aligning to common NMA standards and best practices to provide reliable evidence and appropriately guided clinical decision-making.…”

“…A similar analysis was previously published by the same group (Shear et al [ 2 ]). This publication was subject to scientific criticism by Pettitt et al [ 3 ], as it utilized an analytic approach that is inconsistent with prevailing methodological conventions. At that time, the authors (Shear et al [ 2 ]) chose not to respond nor defend their methodological choices and assumptions.…”